Phillips-Medisize announced an agreement with a biotechnology company to manufacture a wearable, electronic-enabled combination drug device that combines two-day, single use, disposable technology for subcutaneous drug delivery. The combination product is replaced every two days, is about the size of a hockey puck and can be adhered to the patient’s body, via an adhesive patch, or worn near the infusion site.
Phillips-Medisize, which built devices and supplied key data to support the FDA NDA submission, will provide final assembly, testing and quality control of this electronic combination product. Specifically, they will handle the prefilled drug cartridge that fits inside the device. This drug container is aseptically filled and shipped to Phillips-Medisize.
The combination product is slated for launch in 2H 2020. Strong potential also exists to bring the device onto a connected health platform in the future, by embedding connectivity that will make it possible to capture and communicate data between patient and provider in order to help monitor adherence.
